Seres Therapeutics (NASDAQ:MCRB) released its earnings results on Thursday. The biotechnology company reported ($0.54) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.03, Fidelity Earnings reports. Seres Therapeutics had a negative net margin of 264.31% and a negative return on equity of 256.24%. The firm had revenue of $9.06 million for the quarter, compared to analyst estimates of $23.43 million.
Seres Therapeutics stock traded down $0.48 during mid-day trading on Friday, hitting $8.40. The company had a trading volume of 155,488 shares, compared to its average volume of 100,299. The firm has a market capitalization of $330.04 million, a P/E ratio of -3.80 and a beta of 0.61. Seres Therapeutics has a 1 year low of $5.64 and a 1 year high of $11.35. The company has a quick ratio of 2.76, a current ratio of 2.76 and a debt-to-equity ratio of 0.85.
A number of research firms recently weighed in on MCRB. Oppenheimer set a $16.00 target price on shares of Seres Therapeutics and gave the stock a “buy” rating in a research note on Friday. Chardan Capital restated a “buy” rating on shares of Seres Therapeutics in a research note on Sunday, October 28th. BidaskClub lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 25th. ValuEngine lowered shares of Seres Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 30th. Finally, Cantor Fitzgerald set a $15.00 price target on shares of Seres Therapeutics and gave the company a “buy” rating in a research note on Thursday. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $13.81.
A number of institutional investors have recently made changes to their positions in the business. FMR LLC increased its stake in Seres Therapeutics by 0.4% in the third quarter. FMR LLC now owns 6,119,349 shares of the biotechnology company’s stock valued at $46,446,000 after purchasing an additional 23,749 shares during the last quarter. ARK Investment Management LLC increased its stake in Seres Therapeutics by 23.7% in the third quarter. ARK Investment Management LLC now owns 4,040,735 shares of the biotechnology company’s stock valued at $30,669,000 after purchasing an additional 774,307 shares during the last quarter. BlackRock Inc. increased its stake in Seres Therapeutics by 1.8% in the third quarter. BlackRock Inc. now owns 2,281,563 shares of the biotechnology company’s stock valued at $17,318,000 after purchasing an additional 40,719 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Seres Therapeutics by 6.4% in the third quarter. JPMorgan Chase & Co. now owns 421,494 shares of the biotechnology company’s stock valued at $3,199,000 after purchasing an additional 25,287 shares during the last quarter. Finally, Northern Trust Corp increased its stake in Seres Therapeutics by 6.0% in the second quarter. Northern Trust Corp now owns 246,310 shares of the biotechnology company’s stock valued at $2,118,000 after purchasing an additional 14,021 shares during the last quarter. Institutional investors own 77.92% of the company’s stock.
WARNING: “Seres Therapeutics (MCRB) Posts Earnings Results, Beats Expectations By $0.03 EPS” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.com-unik.info/2018/11/10/seres-therapeutics-mcrb-posts-earnings-results-beats-expectations-by-0-03-eps.html.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.